<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05616052</url>
  </required_header>
  <id_info>
    <org_study_id>2022-10-weight loss-SPHCC</org_study_id>
    <nct_id>NCT05616052</nct_id>
  </id_info>
  <brief_title>Comparison of Body Weight Change Through Different Smeglutide Administration Methods</brief_title>
  <official_title>Prospective Randomized Controlled Study on the Improvement of Body Weight Among Overweight and Obese Patients Through Different Smeglutide Administration Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators determined to detect the effect of smeglutide on body weight and metabolic&#xD;
      indexes among overweight and obese participants through two different dosing programs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized into either group. One group will start from 0.25mg per week&#xD;
      for four weeks, then increase to 0.5mg per week for four weeks, and 1mg per week maintenance&#xD;
      dose for 8 weeks. The other group dosage regime depends on the tolerance of the semaglutide&#xD;
      from participants. The dosage will stabilize on the dose how much participant could tolerate.&#xD;
      At the end of 16 weeks treatment, comparison will be carried out on weight change before and&#xD;
      after treatment and (1) Comparison of different administration methods (standards and&#xD;
      titrations) on participant compliance, appetite and quality of life improvement; (2)&#xD;
      Comparison of metabolism (waist hip circumference, body fat and body composition, blood&#xD;
      pressure, blood lipid, blood glucose, insulin resistance) in different administration modes;&#xD;
      (3) Comparison of adverse reactions of metabolic drugs in different administration modes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>weight change in kilograms</measure>
    <time_frame>16 weeks</time_frame>
    <description>weight change in kilograms before and after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>patient compliance in rate</measure>
    <time_frame>16 weeks</time_frame>
    <description>rate of participants dropout of the study（in percentage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>waist hip circumference in centimeter</measure>
    <time_frame>16 weeks</time_frame>
    <description>waist hip circumference in centimeter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>16 weeks</time_frame>
    <description>number of adverse events including hypoglycemia, nausea, vomiting, abdominal pain, diarrhea, constipation, indigestion, burping, flatulence, injection site allergy. Adverse reactions will recorded in percentage (number of participants developed particular adverse reaction divided by all participants in each group, % )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>appetite change in score</measure>
    <time_frame>16 weeks</time_frame>
    <description>appetite change measures in appetite questionnaire (visual analogue scales in assessment of appetite sensations, Units on scale is millimeter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life improvement in score</measure>
    <time_frame>16 weeks</time_frame>
    <description>quality of life improvement (in WHOQOL~BREF, Units on scale is point);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body fat in percentage</measure>
    <time_frame>16 weeks</time_frame>
    <description>body fat in percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition of lean mass in kilogram</measure>
    <time_frame>16 weeks</time_frame>
    <description>body composition in kilogram of lean mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood pressure in mmHg</measure>
    <time_frame>16 weeks</time_frame>
    <description>blood pressure in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood lipid in concentration</measure>
    <time_frame>16 weeks</time_frame>
    <description>blood lipid in including (total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol in mmol/L),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting blood glucose level</measure>
    <time_frame>16 weeks</time_frame>
    <description>fasting blood glucose in milli-mole per liter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-Beta value</measure>
    <time_frame>16 weeks</time_frame>
    <description>the value of 20 × FINS/（FBG-3.5）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total cholesterol in mmol/L</measure>
    <time_frame>16 weeks</time_frame>
    <description>total cholesterolin mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>triglyceride</measure>
    <time_frame>16 weeks</time_frame>
    <description>triglyceride in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>low-density lipoprotein cholesterol</measure>
    <time_frame>16 weeks</time_frame>
    <description>low-density lipoprotein cholesterol in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high-density lipoprotein cholesterol</measure>
    <time_frame>16 weeks</time_frame>
    <description>high-density lipoprotein cholesterol in mmol/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Weight Change, Body</condition>
  <arm_group>
    <arm_group_label>standard arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard arm will start from 0.25mg per week for four weeks, then increase to 0.5mg per week for four weeks, and 1mg per week maintenance dose for 8 weeks..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>titration arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Titration arm dosage regime depends on the tolerance of the semaglutide from patients. The dosage will stabilize on the dose which patients could tolerate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>treatment with different dosage regimes</description>
    <arm_group_label>standard arm</arm_group_label>
    <arm_group_label>titration arm</arm_group_label>
    <other_name>dosage regime</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 ≤ age&lt;75;&#xD;
&#xD;
          2. Overweight or obesity: meet either one of the following standards&#xD;
&#xD;
               1. Patients with BMI ≥ 24 kg/m2 and at least one obesity complication (hypertension,&#xD;
                  hyperlipidemia, apnea syndrome, cardiovascular disease)&#xD;
&#xD;
               2. Simple obese patients with BMI ≥ 28kg/m2&#xD;
&#xD;
               3. Abdominal obesity, waist circumference ≥ 90 cm for males and ≥ 80 cm for females&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a personal or family history of medullary thyroid carcinoma (MTC) or have&#xD;
             multiple endocrine neoplasia type 2 (MEN-2) patients.&#xD;
&#xD;
          2. Patients with severe hypersensitivity to smeglutide or any other excipient component.&#xD;
&#xD;
          3. Diabetic patients (glycosylated hemoglobin ≥ 6.5% or fasting blood glucose ≥ 7.0&#xD;
             mmol/L or blood glucose ≥ 11.1 mmol/L 2 hours after meal or random blood glucose ≥&#xD;
             11.1 mmol/L).&#xD;
&#xD;
          4. Triglyceride&gt;5.6mmol/L;&#xD;
&#xD;
          5. Participants in other clinical drug trials in recent three months.&#xD;
&#xD;
          6. The range of weight change in recent 90 days is&gt;5kg.&#xD;
&#xD;
          7. Cushing's syndrome and abnormal thyroid function.&#xD;
&#xD;
          8. Pregnant or breastfed women.&#xD;
&#xD;
          9. The study doctor judged that it was not suitable to participate in the test.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xiaolong zhao</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Public Health Clinical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xiaolong zhao</last_name>
    <phone>86-13501827230</phone>
    <email>xiaolongzhao@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>xiaolong zhao</last_name>
    <phone>86-021-37990333</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>xiaolong zhao</last_name>
      <phone>86-13501827230</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang Y, Zhao L, Gao L, Pan A, Xue H. Health policy and public health implications of obesity in China. Lancet Diabetes Endocrinol. 2021 Jul;9(7):446-461. doi: 10.1016/S2213-8587(21)00118-2. Epub 2021 Jun 4.</citation>
    <PMID>34097869</PMID>
  </reference>
  <reference>
    <citation>Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48. doi: 10.1038/sj.ijo.0801083.</citation>
    <PMID>10702749</PMID>
  </reference>
  <reference>
    <citation>Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017 Sep;19(9):1242-1251. doi: 10.1111/dom.12932. Epub 2017 May 5.</citation>
    <PMID>28266779</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 5, 2022</study_first_submitted>
  <study_first_submitted_qc>November 6, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>November 6, 2022</last_update_submitted>
  <last_update_submitted_qc>November 6, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>xiaolong zhao</investigator_full_name>
    <investigator_title>Professor of endocrinology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Body Weight Changes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

